At a glance
Nirsevimab Receipt and Intent for Infants
Monthly estimates of receipt and intent for nirsevimab reported by adult females aged 18–49 years with infants under the age of 8 months during the RSV season (born since April 1, 2024) using data from the National Immunization Survey–Adult COVID Module (NIS–ACM). The NIS–ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. All estimates are based upon parent-reported receipt of nirsevimab.
The NIS-ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older.
- Figure 5. Monthly Nirsevimab Receipt and Intent Reported By Females Aged 18–49 Years Who Have an Infant <8 Months during the RSV season (born since April 1, 2024), United States*,†. Data Source: National Immunization Survey–Adult COVID Module.
Note: August 2024 estimates are based on data collected from August 18 through August 31, 2024. For data collected August 18 through September 30, 2024, only intent estimates are available. Parent-reported receipt of nirsevimab will be collected starting October 1, 2024.
Confidence Intervals (CIs) describe the level of uncertainty around an estimate because a sample was taken. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% confidence interval, if the sampling method is repeated many times, the true value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling.
Estimates from the NIS–ACM may differ from estimates based on other data sources, and in addition to random error associated with taking a sample, are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self-reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
Estimates of nirsevimab receipt by infants born since April 1, 2024 include those who were born shortly before or are entering their first RSV season and do not account for the mother’s RSV vaccination status during pregnancy (Healthcare Providers: RSV Immunization for Children 19 Months and Younger | CDC).
*National estimates include 50 states, Washington D.C., Guam, and Puerto Rico.
†Estimates are based on interviews conducted during Sunday through Saturday weeks assigned to the monthly analytic period, which may include some dates in the month before or after the specified analytic month. Unlike the weekly RSV vaccination coverage estimates, they are not cumulative estimates based on all interviews conducted to date.